Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
November 11, 2021 09:00 ET
|
Adaptimmune Therapeutics plc
- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year - - The overall response rate (ORR) per Independent Review was 34% (36% in...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
May 19, 2021 17:00 ET
|
Adaptimmune Therapeutics plc
- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - ...
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
November 19, 2020 09:00 ET
|
Adaptimmune Therapeutics plc
- Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing...
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
July 23, 2020 16:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European...
Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma
November 16, 2019 02:00 ET
|
Adaptimmune Therapeutics plc
- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after...
Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update
November 06, 2019 07:30 ET
|
Adaptimmune Therapeutics plc
- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for...